United Therapeutics Corporation (NASDAQ: UTHR) announced it will present 12 data presentations at the American Thoracic Society International Conference from May 15-20 in Orlando.

The presentations include results from the TETON-1 phase 3 study of inhaled treprostinil in idiopathic pulmonary fibrosis and integrated results from both TETON-1 and TETON-2 studies. The company will also present data from the ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension.

Additional presentations feature interim analysis from the TETON-PPF study of inhaled treprostinil in progressive pulmonary fibrosis, preliminary results from the PHINDER study of patients with interstitial lung disease with and without pulmonary hypertension, and interim results from the ARTISAN study of parenteral treprostinil in pulmonary arterial hypertension.

"We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieved unprecedented results in these two life-threatening diseases," said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics.

The presentations will include both oral sessions and poster presentations scheduled throughout the conference. United Therapeutics will also sponsor several events including patient forums and symposiums on unmet needs in idiopathic pulmonary fibrosis and pulmonary arterial hypertension treatment approaches.

The information is based on a company press release statement.